di-tert-butyl ((2-(((3-chlorophenyl)carbamoyl)imino)-5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-3(2H)-yl)methyl) phosphate | 1185750-06-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: di-tert-butyl ((2-(((3-chlorophenyl)carbamoyl)imino)-5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-3(2H)-yl)methyl) phosphate
• CAS: 1185750-06-4
• 化学式: C₂₇H₃₄ClN₆O₅PS₂
• 分子量: 653.163
• InChiKey: KUQKVEOCRYJZDK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.71
• 重原子数：
  42.0
• 可旋转键数：
  10.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  128.96
• 氢给体数：
  2.0
• 氢受体数：
  11.0

反应信息

• 作为反应物：
  描述：

  di-tert-butyl ((2-(((3-chlorophenyl)carbamoyl)imino)-5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-3(2H)-yl)methyl) phosphate 在 水 、 溶剂黄146 作用下， 以72%的产率得到[2-[(3-Chlorophenyl)carbamoylimino]-5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-3-yl]methyl dihydrogen phosphate
  参考文献：
  名称：

  Water-soluble prodrugs of an Aurora kinase inhibitor

  摘要：

  Compound 1 (SNS-314) is a potent and selective Aurora kinase inhibitor that is currently in clinical trials in patients with advanced solid tumors. This communication describes the synthesis of prodrug derivatives of 1 with improved aqueous solubility profiles. In particular, phosphonooxymethyl-derived prodrug 2g has significantly enhanced solubility and is converted to the biologically active parent (1) following iv as well as po administration to rodents. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.043
• 作为产物：
  描述：

  N-(3-氯苯基)-N’-[5-[2-(噻吩并[3,2-d]嘧啶-4-基氨基)乙基]-2-噻唑基]脲 、 二叔丁基氯甲基磷酸酯 在 sodium hydride 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 以22%的产率得到di-tert-butyl ((2-(((3-chlorophenyl)carbamoyl)imino)-5-(2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl)thiazol-3(2H)-yl)methyl) phosphate
  参考文献：
  名称：

  Water-soluble prodrugs of an Aurora kinase inhibitor

  摘要：

  Compound 1 (SNS-314) is a potent and selective Aurora kinase inhibitor that is currently in clinical trials in patients with advanced solid tumors. This communication describes the synthesis of prodrug derivatives of 1 with improved aqueous solubility profiles. In particular, phosphonooxymethyl-derived prodrug 2g has significantly enhanced solubility and is converted to the biologically active parent (1) following iv as well as po administration to rodents. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.043